{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:49Z","timestamp":1791644629410,"version":"4.3.4"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pccm.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:21:07Z","timestamp":1749813667000},"page":"77-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Achieving remission in severe asthma"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-794X","authenticated-orcid":false,"given":"Sarita","family":"Thawanaphong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-7662","authenticated-orcid":false,"given":"Santi","family":"Nolasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pccm.2025.05.001_bib0001","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/all.15807","article-title":"Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"78","author":"Shin","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0002","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060160","article-title":"Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France","volume":"12","author":"Roche","year":"2022","journal-title":"BMJ Open"},{"issue":"suppl 66","key":"10.1016\/j.pccm.2025.05.001_bib0004","first-page":"4192","article-title":"Prevalence of anxiety and depression in patients with severe asthma who are receiving biologic therapy","volume":"60","author":"Watson","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jadohealth.2007.05.023","article-title":"The prevalence of DSM-IV anxiety and depressive disorders in youth with asthma compared with controls","volume":"41","author":"Katon","year":"2007","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.pccm.2025.05.001_bib0006","article-title":"Beyond direct costs: individual and societal financial burden of asthma in young adults in a Danish nationwide study","volume":"10","author":"H\u00e5kansson","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.pccm.2025.05.001_bib0007","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: frequency, screening and prevention","volume":"30","author":"Fardet","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.pccm.2025.05.001_bib0008","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1097\/CM9.0000000000001853","article-title":"Efficacy and safety of salmeterol\/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis","volume":"134","author":"Zhou","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pccm.2025.05.001_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pccm.2025.05.001_bib0011","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaip.2016.11.030","article-title":"Airway hyperresponsiveness in asthma: measurement and clinical relevance","volume":"5","author":"Nair","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0012","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/02770903.2020.1780255","article-title":"Airway hyperresponsiveness to mannitol improves in both type 2 high and type 2 low asthma after specialist management","volume":"58","author":"Hvidtfeldt","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.pccm.2025.05.001_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2022.04.005","article-title":"Can asthma biologics change the course of disease and induce drug-free remission?","volume":"150","author":"Cohn","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0014","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.05.001_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0016","first-page":"461","article-title":"Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e.\u200aV. (in German)","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.pccm.2025.05.001_bib0017","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00063198-200301000-00003","article-title":"Asthma remission: does it exist?","volume":"9","author":"van den Toorn","year":"2003","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0021","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2003.016246","article-title":"Childhood factors associated with asthma remission after 30 year follow up","volume":"59","author":"Vonk","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.pccm.2025.05.001_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1710-1492-8-16","article-title":"Local and systemic immunological parameters associated with remission of asthma symptoms in children","volume":"8","author":"Waserman","year":"2012","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0023","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0024","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pulmoe.2023.11.004","article-title":"Are we overlooking the lung function in the definition of severe asthma remission?","volume":"30","author":"Nolasco","year":"2024","journal-title":"Pulmonology"},{"key":"10.1016\/j.pccm.2025.05.001_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0026","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/all.16002","article-title":"Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab","volume":"79","author":"Nopsopon","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0027","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: a call for a globally standardised definition","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0028","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1365-2222.2008.02971.x","article-title":"Pathogenesis of asthma","volume":"38","author":"Holgate","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0029","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: http:\/\/www.ginaasthma.org. [Accessed on June 1, 2024]."},{"key":"10.1016\/j.pccm.2025.05.001_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0031","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0032","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2500\/aap.2012.33.3527","article-title":"Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review","volume":"33","author":"Storms","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.pccm.2025.05.001_bib0033","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0034","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/02770903.2024.2361777","article-title":"Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab","volume":"61","author":"Cilli","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.pccm.2025.05.001_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0036","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/jpm13061020","article-title":"Clinical asthma remission obtained with biologics in real life: patients' prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0037","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pccm.2025.05.001_bib0038","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0039","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0041","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0042","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of Mepolizumab in a multicentric spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.pccm.2025.05.001_bib0043","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/biomedicines12050960","article-title":"Evaluation of clinical remission in best-performing severe asthmatic patients treated for three years with mepolizumab","volume":"12","author":"Bagnasco","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.pccm.2025.05.001_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0045","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0046","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0047","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0048","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0049","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0051","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/all.16322","article-title":"Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: a feasibility study","volume":"80","author":"Mukherjee","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0052","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0053","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0054","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.pccm.2025.05.001_bib0056","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.pccm.2025.05.001_bib0057","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0058","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12931-019-1251-3","article-title":"The effectiveness of reslizumab in severe asthma treatment: a real-world experience","volume":"20","author":"Ibrahim","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.pccm.2025.05.001_bib0059","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40733-020-00055-9","article-title":"A comparison of biologicals in the treatment of adults with severe asthma \u2013 real-life experiences","volume":"6","author":"Kotisalmi","year":"2020","journal-title":"Asthma Res Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0061","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.05.001_bib0062","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.05.001_bib0063","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0064","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0065","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0066","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.pccm.2025.05.001_bib0067","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/cea.14544","article-title":"Overcoming barriers to remission in severe eosinophilic asthma: two-year real-world data with benralizumab","volume":"54","author":"Jackson","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0068","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2\u2009years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"key":"10.1016\/j.pccm.2025.05.001_bib0069","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2021","article-title":"Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity","volume":"59","author":"Poznanski","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1164\/rccm.202206-1183OC","article-title":"Autoantibody-mediated macrophage dysfunction in patients with severe asthma with airway infections","volume":"207","author":"Son","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0071","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0072","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0073","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0074","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","article-title":"Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial","volume":"208","author":"Svenningsen","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0076","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0077","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0078","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.05.001_bib0079","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/12034754221130969","article-title":"Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis","volume":"26","author":"Koskeridis","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.pccm.2025.05.001_bib0080","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0081","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0082","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0083","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975914","article-title":"Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response","volume":"13","author":"Duchesne","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1358\/dot.2022.58.12.3449205","article-title":"Tezepelumab for asthma","volume":"58","author":"Nolasco","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.pccm.2025.05.001_bib0086","doi-asserted-by":"crossref","first-page":"293","DOI":"10.18176\/jiaci.1012","article-title":"Role of thymic stromal lymphopoietin in the pathophysiology of asthma and clinical and biological effects of blockade with tezepelumab","volume":"34","author":"Venegas Garrido","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0087","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0088","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0089","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/02770903.2022.2082309","article-title":"One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study","volume":"60","author":"Shinkai","year":"2023","journal-title":"J Asthma"},{"key":"10.1016\/j.pccm.2025.05.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0092","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0094","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult german asthma net severe asthma registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pccm.2025.05.001_bib0095","article-title":"Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: evidence from the Severe Asthma Network in Italy (SANI)","volume":"18","author":"Canonica","year":"2024","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0096","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.05.001_bib0097","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","article-title":"Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial","volume":"166","author":"Thomas","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.pccm.2025.05.001_bib0098","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201911-2298OC","article-title":"Bronchial thermoplasty induced airway smooth muscle reduction and clinical response in severe asthma. The TASMA randomized trial","volume":"203","author":"Goorsenberg","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0099","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaci.2016.08.009","article-title":"Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations","volume":"139","author":"Pretolani","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-017-0554-8","article-title":"Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma","volume":"18","author":"Facciolongo","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0101","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1159\/000491676","article-title":"Bronchial thermoplasty-induced acute airway effects assessed with optical coherence tomography in severe asthma","volume":"96","author":"Goorsenberg","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.pccm.2025.05.001_bib0102","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa064707","article-title":"Asthma control during the year after bronchial thermoplasty","volume":"356","author":"Cox","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0103","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","article-title":"Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial","volume":"181","author":"Castro","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0104","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1164\/rccm.200704-571OC","article-title":"Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma","volume":"176","author":"Pavord","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(20)30408-2","article-title":"Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials","volume":"9","author":"Chaudhuri","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107302","article-title":"Comparing bronchial thermoplasty with biologicals for severe asthma: systematic review and network meta-analysis","volume":"216","author":"Fong","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0107","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/02770903.2023.2297375","article-title":"Pretreatment asthma control test score as a predictive score for clinical remission after bronchial thermoplasty in younger patients with severe asthma and preserved lung function","volume":"61","author":"Kashizaki","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.pccm.2025.05.001_bib0108","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.rmed.2007.05.010","article-title":"Changing pattern of sputum cell counts during successive exacerbations of airway disease","volume":"101","author":"D'Silva","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2013.05.007","article-title":"What is an \"eosinophilic phenotype\" of asthma?","volume":"132","author":"Nair","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0111","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/all.14700","article-title":"Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?","volume":"76","author":"Koenderman","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0112","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0113","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/all.14976","article-title":"Medical algorithms: approach to adult asthma exacerbations","volume":"76","author":"Nair","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0114","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2213-2600(21)00023-0","article-title":"Neutrophilic asthma: misconception or misnomer?","volume":"9","author":"Nair","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/all.13985","article-title":"Mechanisms and therapeutic strategies for non-T2 asthma","volume":"75","author":"Sze","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13223-022-00684-0","article-title":"CFTR heterozygosity in severe asthma with recurrent airway infections: a retrospective review","volume":"18","author":"Priel","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0117","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/all.16011","article-title":"Sputum cytokines associated with raised FeNO after anti-IL5 biologic therapy in severe asthma","volume":"79","author":"Hekking","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.pccm.2025.05.001_bib0118","article-title":"IL-18 biology in severe asthma","volume":"11","author":"Thawanaphong","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pccm.2025.05.001_bib0119","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pccm.2025.05.001_bib0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.alit.2024.03.001","article-title":"Eosinophil-mucus interplay in severe asthma: implications for treatment with biologicals","volume":"73","author":"Venegas Garrido","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.pccm.2025.05.001_bib0121","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202307451","article-title":"A rapid sputum-based lateral flow assay for airway eosinophilia using an RNA-cleaving DNAzyme selected for eosinophil peroxidase","volume":"62","author":"Ali","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.pccm.2025.05.001_bib0122","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1039\/C6AN01563H","article-title":"Development of a functional point-of-need diagnostic for myeloperoxidase detection to identify neutrophilic bronchitis","volume":"141","author":"Wolfe","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.pccm.2025.05.001_bib0123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jpm12010066","article-title":"Multi-omics profiling approach to asthma: an evolving paradigm","volume":"12","author":"Gautam","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104936","article-title":"Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum","volume":"99","author":"Asamoah","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pccm.2025.05.001_bib0125","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaci.2020.07.022","article-title":"eNose breathprints as composite biomarker for real-time phenotyping of complex respiratory diseases","volume":"146","author":"de Vries","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0126","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","article-title":"Spanish consensus on remission in asthma (REMAS)","volume":"60","author":"\u00c1lvarez-Guti\u00e9rrez","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0127","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s41030-024-00262-2","article-title":"Exploring clinical remission in moderate asthma \u2013 perspectives from Asia, the Middle East, and South America","volume":"10","author":"Maneechotesuwan","year":"2024","journal-title":"Pulm Ther"},{"key":"10.1016\/j.pccm.2025.05.001_bib0128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0129","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/02770903.2024.2332351","article-title":"Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma","volume":"61","author":"Martinez-Moragon","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.pccm.2025.05.001_bib0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343362","article-title":"Features of severe asthma response to anti-IL5\/IL5r therapies: identikit of clinical remission","volume":"15","author":"Carpagnano","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2025.05.001_bib0131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.pccm.2025.05.001_bib0132","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pccm.2025.05.001_bib0133","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.pccm.2025.05.001_bib0134","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.3390\/jcm12123953","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with co-presence of bronchiectasis: a real-world multicentre observational study","volume":"12","author":"Campisi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pccm.2025.05.001_bib0135","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pccm.2025.05.001_bib0136","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J Asthma Allergy"}],"container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558825000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558825000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:07:37Z","timestamp":1751018857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772558825000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2772558825000283"],"URL":"https:\/\/doi.org\/10.1016\/j.pccm.2025.05.001","relation":{},"ISSN":["2772-5588"],"issn-type":[{"value":"2772-5588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving remission in severe asthma","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Journal Pulmonary and Critical Care Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pccm.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}